In a longitudinal clinical study to compare two groups, the primary end point is often the time to a specific event (eg, disease progression, death). The hazard ratio estimate is routinely used to ...

When analyzing clinical trial results—especially in oncology—two numbers are central to understanding a drug’s impact: the hazard ratio (HR) and the p-value. Investors often glance at p-values for a ...

We analyzed 54 randomized controlled trials totaling 33,212 patients. The selected outcome was overall survival in 21 (39%) trials. There was evidence of nonproportionality of hazards in 13 (24%) ...

Exposure to greater development intensity linked to reduced stroke risk, with hazard ratio of 0.975. (HealthDay News) — Living in more intensely developed neighborhoods is associated with reduced ...

The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates ...